Article Text
Abstract
Objective To evaluate the success of an intravitreal injection of ocriplasmin to release symptomatic vitreomacular traction (VMT) and close a full-thickness macular hole.
Methods and analysis An observational retrospective multicentre study conducted in Italy. Patients with symptomatic distortion and loss of vision secondary to VMT were included in the study. The patients received a single injection of ocriplasmin and were followed up for 1, 3 and 6 months. Best-corrected visual acuity (BCVA) and spectral domani OCT (SD-OCT) were performed for patient assessment, and adverse events were recorded and analysed.
Results 74 patients (74 eyes) were included in the study. 44 of 74 eyes (59.5%) experienced complete release of the VMT. Macular hole closure was obtained in eight eyes (40%). BCVA improved about three lines after 3 months of follow-up in the patients with VMT resolution in comparison with the patients who did not have VMT resolution (p<0.0001). In 55/74 eyes of 55 patients (74.3%), no adverse events were reported, and most of them were transitory (17/19; 89.5%). The mean time to resolve VMT was 27.4±21.9 days. No cases of retinal tear, retinal detachment or lens destabilisation were observed.
Conclusion Ocriplasmin is a potential alternative treatment for patients with symptomatic VMT and has a good safety profile. A more careful selection of patients, in clinical practice, may increase the success rate.
- retina
- treatment medical
- treatment other
- treatment surgery
- visual perception
- vitreous
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
Footnotes
Contributors SR, FB and TC planned the study. RT, FB, DPM and GV conducted the examinations. SR, FB, TC and GV performed the ocriplasmin injections. GV conducted the statistical analysis. RT is the corresponding author.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent Obtained.
Ethics approval This is an approved retrospective, multicentric, observational case series adherent to the tenets of the Declaration of Helsinki and accepted by our ethics committee (AOUC Careggi, Firenze, Italy).
Provenance and peer review Not commissioned; externally peer reviewed.
Collaborators The Italian Ocriplasmin group: Recchimurzo N, Niro A (Clinica Oculistica Università di Bari), Mariotti C; Orsini E (Clinica Oculistica Università di Ancona); Arpa P, Biraghi L (A.O.S Gerardo); Mura M (Università di Amsterdam); Iannetta D (Clinica oculistica Università di Cagliari); Scialdone A, Radice P (Ospedale oftalmico di Milano); Bruè C, Ramovecchi V (Ospedale di Macerata); Iaculli C (Clinica oculistica Università di Foggia), Morselli S, Cappello E, Toso A (Ospedale di Bassano del Grappa); Romano M (Clinica oculistica Università di Napoli); Caporossi A, Minnella A (Clinica oculistica Università Cattolica di Roma); Staurenghi G, Cereda M (Clinica oculistica Università di Milano); Romani A, Peruzzi S, Pieri B (USL 8 oculistica Arezzo); Lovisolo C, Moretti A (Centro Oculistico Quattroelle); Fanton G (Studio Medico Fanton); De Cillà S (Dipartimento di Scienze della Salute, Università del Piemonte orientale); Traversi C, Tosi Gian M (Clinica Oculistica Università di Siena); Carpineto P, Mastropasqua L (Clinica Oculistica Università di Chieti-Pescara).